SCHEMBL2093920

SCHEMBL2093920

[CH2]CCCCCOCCCCCc1cccc2c1CCCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.36
BAD Q92934 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 2/20 0.34
HTR1A P08908 1/20 0.33
SLC6A4 P31645 1/20 0.33
ALDH1A1 P00352 2/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXRA P19793 5/20 0.32
RXRB P28702 5/20 0.32
RXRG P48443 3/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
MEN1 O00255 1/20 0.32
THRA P10827 1/20 0.32
THRB P10828 1/20 0.32
KMT2A Q03164 1/20 0.32
TBXA2R P21731 1/20 0.32
MRGPRX4 Q96LA9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2099150 0.89 BCL2L1 (0.38) BCL2L1BADSMN1; SMN2LMNAHTR1A
SCHEMBL6003271 0.89 BCL2L1 (0.38) BCL2L1BADSMN1; SMN2LMNAHTR1A
SCHEMBL9115008 0.88 BCL2L1 (0.38) BCL2L1BADSMN1; SMN2LMNAALDH1A1
SCHEMBL6368014 0.85 BCL2L1 (0.44) BCL2L1BADSMN1; SMN2LMNAALDH1A1
SCHEMBL2094732 0.81 LMNA (0.41) BCL2L1BADSMN1; SMN2LMNAHTR1A
SCHEMBL2091729 0.80 LMNA (0.40) BCL2L1BADSMN1; SMN2LMNAHTR1A
SCHEMBL6542272 0.76 ALDH1A1 (0.46) BCL2L1BADLMNASLC6A4ALDH1A1
SCHEMBL9110395 0.75 BCL2L1 (0.42) BCL2L1BADSMN1; SMN2ALDH1A1HTT
SCHEMBL9720039 0.75 BCL2L1 (0.54) BCL2L1BADSMN1; SMN2LMNAALDH1A1
SCHEMBL6542314 0.74 MEN1 (0.43) BCL2L1BADLMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 BCL2L1 2201/4885BAD 2563/4885SMN1; SMN2 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.